•
Mar 31, 2020
Equillium Q1 2020 Earnings Report
Equillium reported financial results for the first quarter of 2020.
Key Takeaways
Equillium reported a net loss of $7.8 million, or $(0.45) per basic and diluted share, for the three months ended March 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $47.7 million at March 31, 2020.
Advanced EQUATE clinical trial for itolizumab in patients with acute graft-versus-host disease (aGVHD).
EQUIP and EQUALISE trials in uncontrolled asthma and lupus nephritis remain paused.
Strengthened the leadership team with the appointments of Maple Fung, M.D., and Matthew Ritter, Ph.D.
Entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC.
Equillium
Equillium
Forward Guidance
Initial data from the Phase 1b part of the EQUATE trial in aGVHD expected in the second half of 2020.